序贯CD19与CD22 CAR-T细胞疗法治疗异基因移植后复发B-ALL
该研究探讨序贯CD19和CD22 CAR-T细胞疗法治疗异基因造血干细胞移植后复发B细胞急性淋巴细胞白血病(B-ALL)的疗效。27例成人和儿童患者(41%伴髓外病变)先接受CD19 CAR-T,85%达完全缓解;其中21例后续接受CD22 CAR-T,中位随访19.7个月,14例维持完全缓解,12个月和18个月总生存率与无事件生存率分别为88.5%和67.5%。
要点
- 序贯CD19/CD22 CAR-T可显著改善移植后复发B-ALL的长期生存。
- 首次CD19 CAR-T后完全缓解率达85%,为后续CD22 CAR-T创造条件。
- CAR-T相关移植物抗宿主病发生率为23%,需关注。
核心结论
- 序贯CD19和CD22 CAR-T细胞疗法显著改善了异基因移植后复发B-ALL患者的长期生存。
研究设计与样本
- 研究纳入27例异基因移植后复发且淋巴母细胞同时表达CD19/CD22的B-ALL成人和儿童患者。
- 使用供者来源细胞制备经慢病毒载体转染的二代CAR-T细胞(含CD3ζ和4-1BB)。
- 第二次CAR-T输注安排在首次治疗后至少1个月,通常6个月内。
主要发现
- 27例中11例(41%)伴有髓外病变,首次CD19 CAR-T后23例(85%)达到完全缓解。
- 27例中21例后续接受CD22 CAR-T,中位随访19.7个月(范围5.6-27.3),14例维持完全缓解,7例复发,其中2例死于疾病进展。
- Kaplan-Meier分析显示12个月和18个月的总生存率均为88.5%,无事件生存率均为67.5%。
- CAR-T相关移植物抗宿主病发生率为23%,其中8%为新发急性GVHD,15%为原有慢性GVHD持续或加重。
临床怎么用
- 对于异基因移植后复发且CD19/CD22双阳性的B-ALL患者,可考虑序贯CD19和CD22 CAR-T细胞疗法。
- 治疗过程中需监测并管理CAR-T相关移植物抗宿主病。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The prognosis of relapsed acute lymphoblastic leukemia (ALL) after allogeneic transplantation is dismal when treated with conventional approaches. While single-target CD19 or CD22 chimeric antigen receptor (CAR) T-cell therapy has achieved high complete remission (CR) rates in refractory/relapsed B-ALL, it could not maintain a durable remission in most patients. To prolong relapse-free survival, we sequentially combined CD19 and CD22 CAR-T cells to treat post-transplant relapsed B-ALL patients with both CD19/CD22 antigen expression on lymphoblasts. Patient-derived donor cells were collected to produce CAR-T cells that were transfected by lentiviral vectors encoding second generation CARs composed of CD3ζ and 4-1BB. The second T-cell infusion was scheduled at least 1 month, and usually within 6 months after the first CAR-T treatment. Twenty-seven adult and pediatric patients, including 11 (41%) with extramedullary diseases (EMD), received the first CD19 CAR-T and 23 (85%) achieved CR. Subsequently, 21 out of 27 patients received the second CD22 CAR-T and were followed-up for a median of 19.7 (range, 5.6-27.3) months; 14 cases remained in CR, seven relapsed and two of them died from disease progression; Kaplan-Meier survival analysis showed overall survival and event-free survival rates of 88.5% and 67.5%, respectively, at both 12 months and 18 months. CAR-T associated graft-versus-host disease (GVHD) occurred in 23% of patients, with 8% new-onset acute GVHD and 15% persistent or worsened pre-existing cGVHD before CAR-T. This combination strategy of sequential CD19 and CD22 CAR-T therapy significantly improved the long-term survival in B-ALL patients who relapsed after transplantation.
引用
- Liu S, Deng B, Yin Z, et al. Combination of CD19 and CD22 CAR-T cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantation. Am J Hematol. 2021. PMID: 33725422. doi:10.1002/ajh.26160
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。